troxacitabine has been researched along with Disease Exacerbation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belanger, K; Bjarnason, GA; Chi, K; Ernst, DS; Goel, R; Jolivet, J; McIntosh, L; Moore, MJ; Ruether, JD; Seymour, L; Siu, LL; Stewart, D; Tannock, I; Townsley, CA | 1 |
| Batist, G; Eatock, M; Hawkins, RE; Jolivet, J; Lapointe, R; Létourneau, R; Moore, M; Steward, W; Vincent, M; Whittom, R | 1 |
2 trial(s) available for troxacitabine and Disease Exacerbation
| Article | Year |
|---|---|
Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Topics: Aged; Antineoplastic Agents; Canada; Carcinoma, Renal Cell; Cytosine; Dioxolanes; Disease Progression; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Treatment Outcome | 2003 |
Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors.
Topics: Adult; Aged; Antineoplastic Agents; Body Weight; Cytosine; Dioxolanes; Disease Progression; Female; Health Status; Humans; Infusions, Intravenous; Male; Middle Aged; Pain; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2005 |